Journal of the American Society of Nephrology, Vol 5, 1888-1894, Copyright © 1995 by American Society of Nephrology

REGULAR ARTICLES

The effects of soluble recombinant complement receptor 1 on complement- mediated experimental glomerulonephritis

WG Couser, RJ Johnson, BA Young, CG Yeh, CA Toth and AR Rudolph
Department of Medicine, University of Washington, Seattle, USA.

Complement is a major mediator of tissue injury in several types of glomerulonephritis. However, no therapeutic agents that inhibit complement activation are available for human use. sCR1 (TP10, BRL 55736) is a recombinant, soluble human complement receptor 1 (CR1) molecule lacking transmembrane and cytoplasmic domains that inhibits C3 and C5 convertase activity by preferentially binding C4b and C3b. To test the efficacy of sCR1 on complement-mediated glomerulonephritis, rats were pretreated with sCR1 (60 mg/kg per day) before and during the induction of three models of complement-dependent glomerulonephritis (concanavalin A and antithymocyte serum models of proliferative glomerulonephritis, passive Heyman nephritis). Daily sCR1 and complement hemolytic activity levels were measured, and renal histology and urine protein excretion were examined. Mean serum sCR1 levels of 100 to 200 micrograms/mL were maintained with a reduction in complement hemolytic activity to less than 15% in most animals. In the antithymocyte serum model, sCR1-treated animals had significant reductions in mesangiolysis, glomerular platelet and macrophage infiltrates, and proteinuria at 48 h. In the concanavalin A model, sCR1 significantly reduced glomerular C3 and fibrin deposits, platelet infiltrates, and proteinuria at 48 h. In passive Heymann nephritis, proteinuria was also significantly reduced (199 +/- 8.5 versus 125 +/- 16 mg/day, P < 0.002) at 5 days. It was concluded that sCR1 significantly reduces both morphologic and functional consequences of several different types of complement-mediated glomerulonephritis and deserves evaluation as a potential therapeutic agent in complement- mediated immune glomerular disease in humans.

This article has been cited by other articles:

				N. S. Bora, S. Kaliappan, P. Jha, Q. Xu, B. Sivasankar, C. L. Harris, B. P. Morgan, and P. S. Bora CD59, a Complement Regulatory Protein, Controls Choroidal Neovascularization in a Mouse Model of Wet-Type Age-Related Macular Degeneration J. Immunol., February 1, 2007; 178(3): 1783 - 1790. [Abstract] [Full Text] [PDF]

				S. P. Berger, A. Roos, and M. R. Daha Complement and the kidney: What the nephrologist needs to know in 2006? Nephrol. Dial. Transplant., December 1, 2005; 20(12): 2613 - 2619. [Full Text] [PDF]

				A. V. Cybulsky, R. J. Quigg, and D. J. Salant Experimental membranous nephropathy redux Am J Physiol Renal Physiol, October 1, 2005; 289(4): F660 - F671. [Abstract] [Full Text] [PDF]

				P. N. Cunningham and R. J. Quigg Contrasting Roles of Complement Activation and Its Regulation in Membranous Nephropathy J. Am. Soc. Nephrol., May 1, 2005; 16(5): 1214 - 1222. [Abstract] [Full Text] [PDF]

				M. Nangaku Complement Regulatory Proteins: Are They Important in Disease? J. Am. Soc. Nephrol., September 1, 2003; 14(9): 2411 - 2413. [Full Text] [PDF]

				S. I-H. Hsu and W. G. Couser Chronic Progression of Tubulointerstitial Damage in Proteinuric Renal Disease Is Mediated by Complement Activation: A Therapeutic Role for Complement Inhibitors? J. Am. Soc. Nephrol., July 1, 2003; 14(90002): S186 - 191. [Abstract] [Full Text] [PDF]

				L. Bao, M. Haas, D. M. Kraus, B. K. Hack, J. K. Rakstang, V. M. Holers, and R. J. Quigg Administration of a Soluble Recombinant Complement C3 Inhibitor Protects Against Renal Disease in MRL/lpr Mice J. Am. Soc. Nephrol., March 1, 2003; 14(3): 670 - 679. [Abstract] [Full Text] [PDF]

				W. G. Couser Complement Inhibitors And Glomerulonephritis: Are We There Yet? J. Am. Soc. Nephrol., March 1, 2003; 14(3): 815 - 818. [Full Text] [PDF]

				H. Pavenstadt, W. Kriz, and M. Kretzler Cell Biology of the Glomerular Podocyte Physiol Rev, January 1, 2003; 83(1): 253 - 307. [Abstract] [Full Text] [PDF]

				D. A. Fraser, C. L. Harris, R. A.G. Smith, and B. P. Morgan Bacterial expression and membrane targeting of the rat complement regulator Crry: A new model anticomplement therapeutic Protein Sci., October 1, 2002; 11(10): 2512 - 2521. [Abstract] [Full Text] [PDF]

				M. G. Robson, H. T. Cook, M. Botto, P. R. Taylor, N. Busso, R. Salvi, C. D. Pusey, M. J. Walport, and K. A. Davies Accelerated Nephrotoxic Nephritis Is Exacerbated in C1q-Deficient Mice J. Immunol., June 1, 2001; 166(11): 6820 - 6828. [Abstract] [Full Text] [PDF]

				J. Hughes, M. Nangaku, C. E. Alpers, S. J. Shankland, W. G. Couser, and R. J. Johnson C5b-9 membrane attack complex mediates endothelial cell apoptosis in experimental glomerulonephritis Am J Physiol Renal Physiol, May 1, 2000; 278(5): F747 - F757. [Abstract] [Full Text] [PDF]

				N. N. Gorgani, J. G. Altin, and C. R. Parish Histidine-rich glycoprotein regulates the binding of monomeric IgG and immune complexes to monocytes Int. Immunol., August 1, 1999; 11(8): 1275 - 1282. [Abstract] [Full Text] [PDF]

				P. H. Pfeifer, M. S. Kawahara, and T. E. Hugli Possible Mechanism for in Vitro Complement Activation in Blood and Plasma Samples: Futhan/EDTA Controls in Vitro Complement Activation Clin. Chem., August 1, 1999; 45(8): 1190 - 1199. [Abstract] [Full Text] [PDF]

				R. J. Quigg, C. He, A. Lim, D. Berthiaume, J. J. Alexander, D. Kraus, and V. Michael Holers Transgenic Mice Overexpressing the Complement Inhibitor Crry as a Soluble Protein Are Protected from Antibody-induced Glomerular Injury J. Exp. Med., October 5, 1998; 188(7): 1321 - 1331. [Abstract] [Full Text] [PDF]

				B. Schiller, C. He, D. J. Salant, A. Lim, J. J. Alexander, and R. J. Quigg Inhibition of Complement Regulation Is Key to the Pathogenesis of Active Heymann Nephritis J. Exp. Med., October 5, 1998; 188(7): 1353 - 1358. [Abstract] [Full Text] [PDF]

				R. J. Quigg, Y. Kozono, D. Berthiaume, A. Lim, D. J. Salant, A. Weinfeld, P. Griffin, E. Kremmer, and V. M. Holers Blockade of Antibody-Induced Glomerulonephritis with Crry-Ig, a Soluble Murine Complement Inhibitor J. Immunol., May 1, 1998; 160(9): 4553 - 4560. [Abstract] [Full Text] [PDF]

				S. C. Makrides Therapeutic Inhibition of the Complement System Pharmacol. Rev., March 1, 1998; 50(1): 59 - 88. [Abstract] [Full Text] [PDF]

				T. E. Mollnes and M. Harboe Recent Advances: Clinical immunology BMJ, June 8, 1996; 312(7044): 1465 - 1469. [Abstract] [Full Text]

Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673